Company intelligence / Profile preview

Fine Japan

Ownership: Private
Employees: ~351
Development stage: Commercial

Overview

Fine Japan offers a broad portfolio of commercialized nutraceuticals and functional foods with established safety certifications. There are no clinical trial results in the pharmaceutical sense; efficacy claims are based on ingredient science and consumer use.

Therapeutic areas: ImmunologyDermatologyRheumatologyGastroenterologyCardiovascular
Modalities: Small moleculeProteinPolysaccharidePeptidesHerbal extract/plant-derived compounds
Industry: Food & Nutrition

Partnerships

Joint research with Konan University Institute of Biotechnology since April 2005

Beyond the preview

Go deeper on Fine Japan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fine Japan.

Explore the full profile